share_log

Rubicon Organics Reports Q1 2024 Financial Results

Rubicon Organics Reports Q1 2024 Financial Results

Rubicon Organics公佈2024年第一季度財務業績
GlobeNewswire ·  05/16 09:26
  • Achieved net revenue of $8.9 million for the three months ended March 31, 2024
  • Adjusted EBITDA1 loss of $0.4 million for the three months ended March 31, 2024
  • Negative operating cash flow of $0.9 million for the three months ended March 31, 2024
  • Number one premium licenced producer across all categories2
  • 2.0%3 national market share of flower and pre-rolls for the three months ended March 31, 2024
  • 7.1%4 national market share of premium flower and pre-rolls for the three months ended March 31, 2024
  • WildflowerTM is the number one topical brand in Canada with market share of 30.6%5 for the three months ended March 31, 2024
  • 22.8%6 national market share of premium edibles for the three months ended March 31, 2024
  • Launch of full spectrum extract vapes in Alberta, BC, and Ontario in May 2024
  • 截至2024年3月31日的三個月,淨收入達到890萬美元
  • 調整後 EBITDA1 截至2024年3月31日的三個月虧損40萬美元
  • 截至2024年3月31日的三個月,運營現金流爲負90萬美元
  • 在所有類別中排名第一的高級許可製片人2
  • 2.0%3 截至2024年3月31日的三個月,鮮花和預卷的全國市場份額
  • 7.1%4 截至2024年3月31日的三個月,優質鮮花和預售花的全國市場份額
  • 野花TM 是加拿大排名第一的熱門品牌,市場份額爲30.6%5 在截至2024年3月31日的三個月中
  • 22.8%6 截至2024年3月31日的三個月,優質零食的全國市場份額
  • 2024 年 5 月在艾伯塔省、不列顛哥倫比亞省和安大略省推出全光譜提取電子煙

VANCOUVER, British Columbia , May 15, 2024 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified, premium cannabis, today reported its financial results for the three months ended March 31, 2024 ("Q1 2024"). All amounts are expressed in Canadian dollars.

不列顛哥倫比亞省溫哥華,2024年5月15日(環球新聞專線)——專注於種植和銷售有機認證優質大麻的持牌生產商Rubicon Organics Inc.(多倫多證券交易所股票代碼:ROMJF)(“Rubicon Organics”、“Rubicon” 或 “公司”)今天公佈了截至2024年3月31日的三個月(“2024年第一季度”)的財務業績。所有金額均以加元表示。

"Rubicon Organics holds the #1 premium position in Canada and is poised for growth with the launch of our full spectrum extract vapes line tapping into the highest growth segment in Canada. With a focus on quality, we are confident that our vape launch will not only drive revenue growth but also solidify our position as a leader in the Canadian cannabis market.

“Rubicon Organics在加拿大擁有 #1 的優質地位,隨着我們的全譜提取電子煙系列的推出,該系列開拓了加拿大增長最快的細分市場,Rubicon Organics有望實現增長。我們注重質量,相信我們推出的vape不僅將推動收入增長,還將鞏固我們在加拿大大麻市場領導者的地位。

"We anticipated a challenging Q1 due to typical seasonality and the overhang of weak consumer sentiment from 2023. I expect to recover from this temporary dip from our streak of positive Adjusted EBITDA in Q2. In Q1, a changing product mix reduced our gross margin, but this spring we've shifted focus to higher-margin products, expecting improved results in Q2 and beyond. Our Q1 working capital investment for product launches is expected to come to fruition delivering further net revenue growth starting in Q2. Additionally, our first-half results are influenced by the ongoing one-time ERP implementation", said Margaret Brodie, CEO.

“由於典型的季節性以及自2023年以來消費者信心疲軟,我們預計第一季度將充滿挑戰。我預計將從第二季度調整後息稅折舊攤銷前利潤持續爲正數的暫時下降中恢復過來。在第一季度,產品組合的變化降低了我們的毛利率,但今年春天我們將重點轉移到利潤率更高的產品上,預計第二季度及以後的業績會有所改善。我們第一季度對產品發佈的營運資本投資預計將實現,從而從第二季度開始進一步實現淨收入增長。此外,我們上半年的業績受到正在進行的一次性ERP實施的影響。” 首席執行官瑪格麗特·布羅迪說。


1 Adjusted EBITDA is a non-GAAP measure that is calculated as earnings (losses) from operations before interest, tax, depreciation and amortization, share-based compensation expense, and fair value changes. Included in Adjusted EBITDA in the three months ended March 31, 2024 is $0.3 million of one-time costs incurred for the ERP implementation project. See Non-GAAP Financial Measures for details on the Adjusted EBITDA calculation.
2Hifyre data for premium products covering flower, pre-rolled products, concentrates, edibles, topicals, and vapes for the three months ended March 31, 2024
3Hifyre data for flower & pre-rolled products covering three months ended March 31, 2024
4Hifyre data for premium flower & pre-rolled products covering three months ended March 31, 2024
5Hifyre data for topical products covering three months ended March 31, 2024
6 Hifyre data for premium edible products covering three months ended March 31, 2024

1 調整後的息稅折舊攤銷前利潤是一項非公認會計准則指標,計算爲扣除利息、稅項、折舊和攤銷前的運營收益(虧損)、基於股份的薪酬支出和公允價值變動。 包含在截至3月31日的三個月的調整後息稅折舊攤銷前利潤中, 2024 是企業資源規劃實施項目產生的一次性費用30萬美元. 參見 非公認會計准則財務指標 了解調整後息稅折舊攤銷前利潤計算的詳細信息。
2Hifyre 優質產品的數據,包括花卉、預軋產品、濃縮物、食品、外用藥和電子煙 截至3月31日的三個月,2024
3Hifyre 花卉和預軋產品的數據涵蓋範圍 截至3月31日的三個月,2024
4Hifyre 的數據爲 保費 花卉和預軋產品覆蓋 截至3月31日的三個月,2024
5Hifyre 涵蓋的外用產品數據 截至3月31日的三個月,2024
6 Hifyre 優質可食用產品的數據包括 截至3月31日的三個月,2024

Janis Risbin, CFO, said "Despite the market challenges, we've managed to maintain revenue levels in line with Q1 2023, a testament to our resilience and adaptability. With the expected re-financing of our debt later this year, we remain focused on strengthening our already solid foundation and continuing to invest opportunistically for growth in 2024 and beyond."

首席財務官賈尼斯·里斯賓表示:“儘管面臨市場挑戰,但我們設法將收入水平維持在2023年第一季度的水平,這證明了我們的彈性和適應能力。預計將在今年晚些時候對債務進行再融資,我們將繼續專注於鞏固本已堅實的基礎,並繼續爲2024年及以後的增長進行機會性投資。”

Q1 2024 and Subsequent Highlights:
For the three months ended March 31, 2024

2024 年第一季度及後續亮點:
在截至2024年3月31日的三個月中

  • Net revenue of $8.9 million (1% increase from Q1 2023)
  • Gross profit before fair value adjustments of $2.2 million (28% decrease from Q1 2023)
  • Adjusted EBITDA1 loss of $0.4 million compared to profit of $1.7 million in Q1 2023
  • Cash used by operating activities was $0.9 million compared to cash provided by operating activities of $0.2 million in Q1 2023
  • Number one premium licenced producer across all categories7
  • 2.0%8 national market share of flower and pre-rolls
  • 7.1%3 national market share of premium flower and pre-rolls
  • 30.6%4 national market share of topical products
  • 6.7%9 national market share of premium concentrates
  • 22.8%10 national market share of premium edibles
  • Launch of 1964 Supply Co.TM full spectrum extract ("FSE") vapes, initially available for Blue Dream and Comatose, with purchase orders received from Alberta, BC and Ontario.
  • 淨收入爲 890 萬美元(比 2023 年第一季度增長 1%)
  • 公允價值調整前的毛利爲220萬美元(較2023年第一季度下降28%)
  • 調整後 EBITDA1 虧損40萬美元,而2023年第一季度的利潤爲170萬美元
  • 經營活動使用的現金爲90萬美元,而2023年第一季度運營活動提供的現金爲20萬美元
  • 在所有類別中排名第一的高級許可製片人7
  • 2.0%8 鮮花和預卷的全國市場份額
  • 7.1%3 優質鮮花和預卷的全國市場份額
  • 30.6%4 外用產品的全國市場份額
  • 6.7%9 優質濃縮物的全國市場份額
  • 22.8%10 優質零食的全國市場份額
  • 1964 年供應公司成立TM 全光譜提取物(“FSE”)電子煙,最初可用於Blue Dream和Comatose,採購訂單來自不列顛哥倫比亞省和安大略省。

7Hifyre data for premium products covering flower, pre-rolled products, concentrates, edibles, topicals, and vapes for the three months ended March 31, 2024
8Hifyre data for flower & pre-rolled products covering twelve months ending March 31, 2024
9Hifyre data for premium concentrates products covering twelve months ending March 31, 2024
10Hifyre data for premium edible products covering twelve months ending March 31, 2024

7Hifyre 優質產品的數據,包括花卉、預軋產品、濃縮物、食品、外用藥和電子煙 截至3月31日的三個月,2024
8Hifyre 花卉和預軋產品的數據涵蓋範圍 十二 月結束 三月 31,2024
9Hifyre 的數據爲 優質濃縮物 產品覆蓋 十二 月結束 三月 31,2024
10Hifyre 涵蓋十二個月的優質食用產品數據 結尾 三月 31,2024

2024 Results of Operations:

2024 年經營業績:

Three months ended
March 31, 2024
$
March 31, 2023
$
Net revenue 8,890,417 8,799,940
Production costs 2,692,692 2,678,604
Inventory expensed to cost of sales 3,737,334 2,934,894
Inventory written off or provided for 266,039 157,424
Gross profit before fair value adjustments 2,194,352 3,029,018
Fair value adjustments to cannabis plants, inventory sold, and other charges 164,252 139,463
Gross profit 2,358,604 3,168,481
三個月已結束
2024年3月31日
$
2023年3月31日
$
淨收入 8,890,417 8,799,940
製作成本 2,692,692 2,678,604
庫存費用計入銷售成本 3,737,334 2,934,894
註銷或提供的庫存 266,039 157,424
公允價值調整前的毛利 2,194,352 3,029,018
對大麻植物、已售庫存和其他費用的公允價值調整 164,252 139,463
毛利 2,358,604 3,168,481
As At: March 31,
2024
$
December 31,
2023
$
Cash and cash equivalents 8,121,134 9,784,190
Working capital † 9,554,365 10,132,089
截至日期: 3月31日
2024
$
十二月 31,
2023
$
現金和現金等價物 8,121,134 9,784,190
營運資金 † 9,554,365 10,132,089

† Working capital as at March 31, 2024 includes $10.7 million current portion of loans and borrowings. The Company is currently in discussions with the debenture holder and other lenders to extend the term of the existing agreement or to enter into a new loan agreement in the second half of 2024.

† 截至2024年3月31日,營運資金包括1,070萬美元的流動貸款和借款。該公司目前正在與債券持有人和其他貸款人進行討論,以延長現有協議的期限或在2024年下半年簽訂新的貸款協議。

2024 Outlook

2024 年展望

Brand and Product Development

品牌和產品開發

Our strategy is founded on a strong premium branded portfolio, highly regarded by both budtenders and consumers alike. Guided by consumer research, we continually innovate our products to anticipate market trends. Our commitment to quality and excellence is evident throughout all areas of our business, seeking to deliver products and services that consistently meet the highest quality standards.

我們的戰略建立在強大的高端品牌組合基礎上,受到招商和消費者的高度評價。在消費者研究的指導下,我們不斷創新產品以預測市場趨勢。我們對質量和卓越的承諾體現在我們業務的各個領域,我們力求提供始終符合最高質量標準的產品和服務。

Launch into Vape Category

進入電子煙類別

Rubicon is launching into the vape category with our 1964 Supply CoTM brand. The introduction of vapes strategically aligns with our market expansion strategy and offers substantial growth prospects. The vape market has demonstrated robust growth over recent years and trends in Canada and the US demonstrate indicating the vape category's increasing prominence, rivaling or surpassing traditional flower products.

Rubicon將以我們1964年的Supply CoTM品牌進入電子煙類別。電子煙的推出在戰略上符合我們的市場擴張戰略,並提供了可觀的增長前景。近年來,電子煙市場表現出強勁的增長,加拿大和美國的趨勢表明,該電子煙類別越來越突出,可與傳統花卉產品相媲美或超越。

Our launch into the vape category takes advantage of additional biomass available from our contract grow strategy launched in 2023 of our own genetics grown outside of the Delta Facility. We have received initial purchase orders for our Comatose and Blue Dream Full Spectrum Extract ("FSE") resin vapes in Ontario, BC, and Alberta which are all expected to be delivered in May 2024 to the provincial distributors and available for purchase in retail stores shortly thereafter.

我們進入電子煙類別利用了我們於2023年啓動的合同種植戰略中可獲得的額外生物質,這些戰略是我們在三角洲設施之外培育的自己的遺傳學。我們已經收到了位於安大略省、不列顛哥倫比亞省和艾伯塔省的Comatose和Blue Dream全光譜提取物(“FSE”)樹脂電子煙的初始採購訂單,預計都將於2024年5月交付給省級分銷商,並在此後不久可在零售商店購買。

In line with our approach to the live rosin edibles we launched under the brand in 2023, we are focused on delivering products that maintain a competitive edge through superior quality, right price to value ratio leveraging our established and reputable brands. We are confident that by capitalizing on this opportunity, over time we can achieve comparable financial success with our vape offerings as we have with our flower business.

根據我們在2023年以該品牌推出的活松香零食的方法,我們專注於利用我們知名和信譽良好的品牌,提供通過卓越的質量、合理的性價比來保持競爭優勢的產品。我們相信,通過抓住這個機會,隨着時間的推移,我們的電子煙產品可以取得與花卉業務相似的財務成功。

WildflowerTM's Leadership in Cannabis Wellness

野花TM在大麻健康領域的領導地位

WildflowerTM's prominence in the cannabis wellness sector is characterized by its notable dominance in topical products and the Company has recently expanded the brand to other categories, including edibles, oils, and capsules designed to address specific wellness needs such as sleep, pain relief, and anxiety reduction. While we expect more competition to enter the topical and wellness category, we are expanding the brand into other categories and anticipate steady growth and momentum behind the daily wellness consumer.

野花TM其在大麻健康領域的突出地位以其在外用產品中的顯著主導地位爲特徵,該公司最近將該品牌擴展到其他類別,包括旨在滿足睡眠、緩解疼痛和減輕焦慮等特定健康需求的食品、油和膠囊。儘管我們預計主題和健康類別將出現更多競爭,但我們正在將該品牌擴展到其他類別,並預計日常健康消費者將保持穩步增長和勢頭。

Launch of New Genetics

新遺傳學的推出

Rubicon plans to continue to launch new and novel genetics into its Simply BareTM Organic and 1964 Supply CoTM to continue leadership in the premium cannabis market. Launches in 2024 include BC Organic Zookies, BC Organic Power Mintz, and BC Organic Fruit Loopz under the Simply Bare TM Organic brand, and Blue Dream under the 1964 Supply CoTM brand.

Rubicon計劃繼續在其Simply BareTM Organic和1964年的Supply CoTM中推出新的和新型的遺傳學,以保持在優質大麻市場的領導地位。2024年推出的產品包括Simply Bare TM Organic品牌下的BC Organic Zookies、BC Organic Power Mintz和BC Organic Fruit Loopz,以及1964年Supply CoTM品牌下的Blue

Growth from Solid Business Fundamentals

穩健的業務基礎帶來增長

Consistent quality and systematic delivery to our customers, including the provincial distributors and retailers, and consumers to meet their needs is imperative to be successful in the Canadian cannabis industry. In 2024 we are investing in an Enterprise Resource Planning ("ERP") system which is necessary for our business to deliver more growth in future and allow less reliance on key people within our internal systems. Anticipated project costs for 2024 are estimated to reach $1 million, with $0.3 million incurred in the first three months of 2024. While a resource intensive process, this ERP implementation readies our business for growth in future.

爲我們的客戶(包括省級分銷商和零售商以及消費者)提供穩定的質量和系統的交付,以滿足他們的需求,是加拿大大麻行業取得成功的必要條件。2024年,我們將投資企業資源規劃(“ERP”)系統,這是我們的業務在未來實現更多增長並減少對內部系統中關鍵人員的依賴所必需的。2024年的預期項目成本估計將達到100萬美元,其中30萬美元將在2024年前三個月產生。雖然這是一個資源密集型的過程,但這種ERP的實施使我們的業務爲未來的增長做好了準備。

Financial

金融

We believe that our commitment to cannabis quality, strategic brand positioning, diverse product portfolio, and committed team will position us as one of the premier cannabis companies in Canada. We anticipate year over year growth in net revenue, supported by modest increases in our cost base, excluding the impact of the ERP implementation occurring mostly in the first half, thereby enhancing our operating leverage. While we expect growth in 2024, we also anticipate that much of the growth will come from our branded products that are produced using external capacity and thereby deliver lower gross margin than our current mix. Furthermore, we expect continued fierce competition in the distressed Canadian cannabis industry with price compression across all categories. Notwithstanding these pressures, we expect to deliver continued operating positive cash flow in the year ahead and plan to refinance our debt to a longer-term mortgage facility in the second half of 2024.

我們相信,我們對大麻質量、戰略品牌定位、多元化產品組合和敬業團隊的承諾將使我們成爲加拿大首屈一指的大麻公司之一。我們預計,在成本基礎適度增加的支持下,淨收入將同比增長,其中不包括主要發生在上半年的ERP實施的影響,從而提高了我們的運營槓桿率。雖然我們預計2024年將實現增長,但我們也預計大部分增長將來自我們的品牌產品,這些產品是使用外部產能生產的,因此毛利率低於我們目前的組合。此外,我們預計,陷入困境的加拿大大麻行業將持續激烈競爭,所有類別的價格都將壓縮。儘管有這些壓力,但我們預計未來一年將繼續提供正的運營現金流,並計劃在2024年下半年將債務再融資到長期抵押貸款額度。

Conference Call

電話會議

The Company will be hosting a conference call to discuss Q1 2024 results on Thursday, May 16, 2024. Conference call details are as follows:

該公司將於2024年5月16日星期四舉行電話會議,討論2024年第一季度的業績。電話會議詳情如下:

Time: 7:00 AM PT / 10:00 AM ET
Conference ID: 30069
Local dial-in: +1 (289) 514 5100
Toll Free N. America: +1 (800) 717 1738
Webcast:
時間: 太平洋時間上午 7:00 /美國東部時間上午 10:00
會議編號: 30069
本地撥入: +1 (289) 514 5100
北美免費電話: +1 (800) 717 1738
網絡直播:


ABOUT RUBICON ORGANICS INC.


關於 RUBICON ORGANICS INC.

Rubicon Organics Inc. is the global brand leader in premium organic cannabis products. The Company is vertically integrated through its wholly owned subsidiary Rubicon Holdings Corp, a licensed producer. Rubicon Organics is focused on achieving industry leading profitability through its premium cannabis flower, product innovation and brand portfolio management, including three flagship brands: its super-premium brand Simply Bare Organic, its premium brand 1964 Supply Co, and its cannabis wellness brand Wildflower in addition to the Company's mainstream brand Homestead Cannabis Supply.

Rubicon Organics Inc. 是優質有機大麻產品的全球品牌領導者。該公司通過其全資子公司Rubicon Holdings Corp(一家持牌生產商)實現垂直整合。Rubicon Organics專注於通過其優質大麻花、產品創新和品牌組合管理實現行業領先的盈利能力,其中包括三個旗艦品牌:其超高端品牌Simply Bare Organic、其高端品牌1964 Supply Co和其大麻健康品牌Wildflower,以及該公司的主流品牌Homestead Cannabis Supply。

The Company ensures the quality of its supply chain by cultivating, processing, branding and selling organic certified, sustainably produced, super-premium cannabis products from its state-of-the-art glass roofed facility located in Delta, BC, Canada.

該公司通過其位於加拿大不列顛哥倫比亞省三角洲的最先進的玻璃屋頂設施種植、加工、品牌推廣和銷售經有機認證、可持續生產的超優質大麻產品,從而確保其供應鏈的質量。

CONTACT INFORMATION

聯繫信息

Margaret Brodie
CEO
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

瑪格麗特·布羅迪
首席執行官
電話:+1 (437) 929-1964
電子郵件:ir@rubiconorganics.com

The TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

多倫多證券交易所風險交易所或其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)對本新聞稿的充分性或準確性不承擔任何責任。

Non-GAAP Financial Measures

非公認會計准則財務指標

This press release contains certain financial performance measures that are not recognized or defined under IFRS ("Non-GAAP Measures") including, but not limited to, "Adjusted EBITDA". As a result, this data may not be comparable to data presented by other companies.

本新聞稿包含某些未被國際財務報告準則認可或定義的財務業績指標(“非公認會計准則指標”),包括但不限於 “調整後的息稅折舊攤銷前利潤”。因此,該數據可能無法與其他公司提供的數據進行比較。

The Company believes that these Non-GAAP Measures are useful indicators of operating performance and are specifically used by management to assess the financial and operational performance of the Company as well as its liquidity. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. For more information, please refer to the "Selected Financial Information" section in the MD&A for the year ended December 31, 2023, which is available on SEDAR+ at .

公司認爲,這些非公認會計准則指標是衡量經營業績的有用指標,管理層專門用於評估公司的財務和運營業績及其流動性。因此,不應孤立地考慮它們,也不能取代對我們根據國際財務報告準則報告的財務信息的分析。欲了解更多信息,請參閱截至2023年12月31日的年度管理與分析報告中的 “精選財務信息” 部分,該部分可在以下網址查閱 SEDAR+ 在。

Adjusted EBITDA

調整後 EBITDA

Below is the Company's quantitative reconciliation of Adjusted EBITDA calculated as earnings (losses) from operations before interest, tax, depreciation and amortization, share-based compensation expense, and fair value changes. The following table presents the Company's reconciliation of Adjusted EBITDA to the most comparable IFRS financial measure for the three months ended March 31, 2024, March 31, 2023, and December 31, 2023.

以下是公司調整後息稅折舊攤銷前利潤的量化對賬表,計算方法是扣除利息、稅項、折舊和攤銷前的運營收益(虧損)、基於股份的薪酬支出和公允價值變動。下表顯示了公司截至2024年3月31日、2023年3月31日和2023年12月31日的三個月,調整後息稅折舊攤銷前利潤與最具可比性的國際財務報告準則財務指標的對賬情況。

Three months ended
March 31,
2024
March 31,
2023
December 31,
2023
$ $ $
Profit (loss) from operations (1,738,486) (304,497) 889,166
IFRS fair value accounting related to cannabis plants and inventory (164,252) (139,463) (829,800)
Depreciation and amortization 776,680 744,783 793,006
Share-based compensation expense 702,846 (132,158) 440,491
Adjusted EBITDA ‡ (423,212) 168,665 1,292,863
三個月已結束
3月31日
2024
3月31日
2023
十二月三十一日
2023
$ $ $
運營利潤(虧損) (1,738,486) (304,497) 889,166
與大麻植物和庫存相關的國際財務報告準則公允價值會計 (164,252) (139,463) (829,800)
折舊和攤銷 776,680 744,783 793,006
基於股份的薪酬支出 702,846 (132,158) 440,491
調整後的息稅折舊攤銷前利潤 (423,212) 168,665 1,292,863

Included in Adjusted EBITDA in the three months ended March 31, 2024 is $0.3 million of one-time costs incurred for the ERP implementation project.

截至2024年3月31日的三個月,調整後的息稅折舊攤銷前利潤中包括ERP實施項目產生的30萬美元一次性成本。

Cautionary Statement Regarding Forward Looking Information

關於前瞻性信息的警示聲明

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Rubicon Organics' goal of achieving industry leading profitability are "forward-looking statements". Forward-looking information can be identified by the use of words such as "will" or variations of such word or statements that certain actions, events or results "will" be taken, occur or be achieved.

本新聞稿包含適用證券法所指的前瞻性信息。所有非歷史事實的陳述,包括但不限於有關未來估計、計劃、計劃、預測、預測、目標、假設、預期或未來業績信念的陳述,以及關於Rubicon Organics實現行業領先盈利目標的陳述,均爲 “前瞻性陳述”。前瞻性信息可以通過使用 “意願” 之類的詞語或此類詞語的變體來識別,這些詞或陳述是 “將” 採取、發生或實現的某些行動、事件或結果。

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including the impact on revenue of new products and brands entering the market, and the timing of achieve Adjusted EBITDA1 profitability and cashflow positive. Risks and uncertainties associated with the forward looking information in this press release include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits for construction at its facilities in a timely manner; regulatory or political change such as changes in applicable laws and regulations, including bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; Rubicon Organics' limited operating history and lack of historical profits; reliance on management; and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers; and those factors identified under the heading "Risk Factors" in Rubicon Organic's annual information form dated March 27, 204 filed with Canadian provincial securities regulatory authorities.

此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際結果、事件或發展與此類前瞻性陳述所表達或暗示的任何未來業績、事件或發展存在重大差異。本新聞稿中的前瞻性信息基於管理層認爲在某些情況下合理的假設,包括新產品和品牌進入市場對收入的影響,以及實現調整後息稅折舊攤銷前利潤的時機1 盈利能力和現金流爲正。與本新聞稿中的前瞻性信息相關的風險和不確定性包括,對獲得和維持監管部門批准的依賴性,包括獲得和續訂聯邦、省、地方或其他許可證,以及無法及時獲得所有必要的政府批准、許可和設施施工許可證;監管或政治變化,例如適用法律和法規的變化,包括官僚主義延誤或效率低下或任何其他原因;任何其他因素或可能阻礙市場增長的事態發展;Rubicon Organics有限的運營歷史和缺乏歷史利潤;對管理的依賴;以及資本市場狀況和其他因素對資本可用性的影響;競爭,包括來自更成熟或資金充足的競爭對手的競爭;以及確保和維持企業聯盟和夥伴關係,包括與客戶和供應商的聯盟和夥伴關係的必要性;以及Rubicon Organic於2004年3月27日提交的年度信息表中 “風險因素” 標題下確定的因素加拿大省級證券監管機構。

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although Rubicon Organics has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

應仔細考慮這些因素,並提醒讀者不要過分依賴此類前瞻性陳述。儘管Rubicon Organics試圖確定可能導致實際行動、事件或結果與前瞻性陳述中描述的存在重大差異的重要風險因素,但可能還有其他風險因素導致行動、事件或結果與預期、估計或預期的不同。無法保證前瞻性陳述會被證明是準確的,因爲實際結果和未來事件可能與前瞻性陳述中的預期存在重大差異。除非法律要求,否則Rubicon Organics不承擔更新任何前瞻性陳述的義務,即使由於未來事件、新信息或任何其他原因而獲得新信息。

We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: optimizing yield, achieving revenue growth, increasing gross profit, operating cashflow and Adjusted EBITDA1 profitability. Even though the management of Rubicon Organics believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Investors are cautioned against undue reliance on forward-looking statements or information. Forward-looking statements and information are designed to help readers understand management's current views of our near and longer term prospects and may not be appropriate for other purposes. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, changes in assumptions, new information or for any other reason except as required by law.

我們對其中包含的前瞻性陳述和信息做出了許多假設,其中包括:優化收益率、實現收入增長、增加毛利、運營現金流和調整後息稅折舊攤銷前利潤1 盈利能力。儘管Rubicon Organics的管理層認爲所做的假設以及此類陳述或信息所代表的預期是合理的,但無法保證前瞻性信息會被證明是準確的,因爲實際結果和未來事件可能與前瞻性陳述中的預期存在重大差異。提醒投資者不要過度依賴前瞻性陳述或信息。前瞻性陳述和信息旨在幫助讀者了解管理層當前對我們短期和長期前景的看法,可能不適用於其他目的。Rubicon Organics不承擔更新任何前瞻性陳述的義務,即使由於未來事件、假設的變化、新信息或法律要求以外的任何其他原因而獲得新信息。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論